A biopharmaceutical business focused on discovering.
AVEO’s successful use of its genetically designed mouse models to find these human-relevant biomarkers demonstrates the potential of AVEO’s preclinical tumor models in individual response prediction. ‘We believe these assessments reflect different aspects of the same underlying tumor biology and have potential for development as companion diagnostics in a wide selection of tumor types. Ongoing research involving these tests will help AVEO make educated decisions as we explore the use of these biomarkers inside our clinical programs,’ commented Tuan Ha-Ngoc, president and chief executive officer of AVEO Pharmaceuticals.The 3rd writer initiated the trial; the first author designed the pathological-final result study. Patient recruitment and randomization and assortment of outcome data were executed by the NSABP. Participating sites sent sentinel-lymph-node blocks to the University of Vermont for an assessment that was funded by the National Cancers Institute. These data were linked with trial end result data by the NSABP, were used in the University of Vermont in a format that removed identifying characteristics of the individuals, and had been analyzed by the second author.